艾伯維藥廠為美國藥價談判率先撥備21億美元
艾伯維(AbbVie)(ABBV.US)周五披露,一旦美國醫療保險患者的新價格生效,收入預計將下降,公司已為其暢銷抗癌藥物Imbruvica因美國政府價格談判而撥備21億美元。
艾伯維旗下白血病藥物於8月被選為美國醫療保險計劃首次價格談判的10種藥物之一,政府明確的目標是到2031年每年節省250億美元藥物成本。10種藥物新價格尚未協商,新價格亦需要2026年才會生效。
不過,艾伯維表示,已估計未來現金流量將大幅下降。Imbruvica第三季銷售額為9.08億美元,超過華爾街預期的8.63億美元。
艾伯維第三季營收為139.3億美元,超出預期的137.1億美元;調整後每股盈利2.95美元,超出分析師預期9美仙。同時,上調2023年調整後每股利潤,介乎於11.19美元至11.23美元,高於本月稍早預測的10.86美元至11.06美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.